peptidylarginine deiminase 4 inhibitor (Angion Biomedica)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namepeptidylarginine deiminase 4 inhibitor (Angion Biomedica)
Drug Alias NamePAD 4 inhibitor (Angion Biomedica)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein-arginine deiminase type-4 inhibitors
TargetsProtein-arginine deiminase type-4
Therapy Area/IndicationsRenal InsufficiencyPancreatic DiseasesHepatic Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesElicio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElicio Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsRenal InsufficiencyPancreatic DiseasesHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A